Risedronate Sodium and Tirofiban Hydrochloride

Abstract

Each month, subscribers to The Formulary® receive print and electronic versions of at least six monographs reviewing new drug entities or related drugs within a category. Some reviews take a second look at currently available drugs, whereas other preliminarily evaluate agents about to be released—just in time for use with your Pharmacy and Therapeutics Committee or for counter detailing. The monographs are prepared by clinical and drug-information pharmacists and are reviewed by expert pharmacists and physicians. Through the cooperation of The Formulary, Hospital Pharmacy has arranged to publish selected reviews in this column. If you would like more information about The Formulary or its related electronic bulletin board, known as the F.I.X.® (Formulary Information Exchange, write to: The Formulary, 33971 Selva Road, Suite 250, Dana Point CA 92629; or call 1-800-322–4349.

Get full access to this article

View all access options for this article.

References

Actonel package literature. Procter and Gamble Pharmaceuticals; March 1998.

White

, ed. Mosby's GenRx 1998. St. Louis, MO: Mosby; 1998.

Hebel

, ed. Drug Facts and Comparisons: Loose-Leaf Edition. St. Louis, MO: Facts and Comparisons, Inc.; 1997.

Fosamax package literature. Merck and Co., Inc.; April 1997.

Skelid package literature. Sanofi Pharmaceuticals, Inc.; March 1997.

Hosking

D.J.

Paget's disease of bone: Reduction of disease activity with oral risedronate. Bone. 1998; 22: 51–55.

Meunier

P.J.

, Vignot

Therapeutic strategy in Paget's disease of bone. Bone. 1995; 17(Suppl): 489S–491S.

Sansom

L.N.

Human pharmacokinetics of tiludronate. Bone. 1995; 17(suppl): 479S–483S.

Patel

Changes in bone mineral density in patients with Paget's disease treated with risedronate. Ann Rheum Dis. 1997; 56: 405–409.

10.

Brown

J.P.

Risedronate in Paget's disease: Preliminary results of a multicenter study. Semin Arthritis Rheum. 1994; 23: 272.

11.

Francis

R.M.

Bisphosphonates in the treatment of osteoporosis in 1997: A review. Curr Ther Res. 1997; 58: 656–678.

12.

Anonymous. Study results highlight the promise of risedronate in treating postmenopausal women with low bone mass. PR Newswire. Sept 11, 1997. (http://www.prnewswire.com).

13.

Anonymous. P&G/HMR Actonel Paget's launch and osteoporosis filing set for autumn. The Pink Sheet. 1998; 60(14): 3.

14.

Clemmesen

A 2-year phase II study with 1-year of follow-up of rise-dronate (NE-58095) in postmenopausal osteoporosis. Osteoporos Int. 1997; 7: 488–495.

15.

Mortensen

Risedronate increases bone mass in an early postmenopausal population: Two years of treatment plus one year of follow-up. J Clin Endocrinol Metab. 1998; 83: 396–402.

16.

Delmas

P.D.

Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double-blind, placebo-controlled study. J Clin Oncol. 1997; 15: 955–962.